SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE:NVTA), a genetic information company, today announced that it has expanded its genetic testing offering with hundreds of additional genes and ...

SAN FRANCISCO-- (BUSINESS WIRE)-- Invitae Corporation (NYSE:NVTA), a genetic information company, and TME Research, LLC today announced the initiation of a new clinical collaboration to evaluate the ...

Though expected to cost Invitae between $75 million and $100 million to carry out, the efforts are ultimately projected to save Invitae around $326 million per year. (Invitae) Overseen by a newly ...

-- New sponsored testing program can make it easier for patients to receive genetic testing in Parkinson's disease, early-onset Alzheimer's disease, ALS and other common conditions -- SAN FRANCISCO, ...

What is a winner-take-most market? The long term profitability and success of any company is highly dependent on the market in which it operates. Many markets have low barriers to entry; many sellers ...

Invitae Corporation (NYSE: NVTA), a genetic information company, has announced that it has more than doubled the size of its genetic testing platform to include more than 600 genes and will begin ...

SAN FRANCISCO, July 18, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced a comprehensive plan to realize the full potential of its industry-leading ...

SAN FRANCISCO, June 13, 2018 /PRNewswire/ -- Researchers from Invitae, one of the fastest growing genetics companies, today published findings from the largest analysis to date of genetic testing to ...

Last year, Invitae ($NVTA) said that it was aiming to expand its test menu to more than 1,000 genes by mid-2016. Now, the company has achieved that goal ahead of ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...